The aim of the retrospective study was to evaluate prognostic significance of human papillomavirus (HPV) status and expression of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor type 2 (HER2/neu), vascular endothelial growth factor (VEGF), CD34 antigen, tumor suppressors p63 and p53, and Ki67/MIB-1 in squamous cell carcinoma of the uterine cervix (SCCC) treated with radiotherapy or chemoradiotherapy. Seventy-two consecutive patients with SCCC, diagnosed and treated with (chemo-) radiotherapy with a curative intent at the University Hospital Hradec Kralove between August 1998 and August 2008, were enrolled in the study. The median follow-up period was 57 months (range 5-152). The tested biological factors were evaluated by polymerase chain reaction (HPV status) and by immunohistochemistry (remaining above mentioned markers) from archival paraffin embedded original diagnostic tumor samples. A statistical significant correlation was observed between low expression of p63 and poor overall survival (p = 0.001), although the complete response probability was influenced with borderline statistical significance (p = 0.05). However, the results could be affected by the statistical error due to the small number of p63 negative patients. HPV positivity and EGFR staining intensity was associated with higher complete response probability (p = 0.038 and p = 0.044, resp.). All other results were not significant. Neither HPV positivity nor EGFR staining intensity were reflected in the overall survival evaluation. In conclusion, the presented study did not confirm any apparently significant association of the suggested markers with prognosis of SCCC in patients treated with (chemo-) radiotherapy.

Department of Oncology and Radiotherapy University Hospital Hradec Kralove Sokolská 581 500 05 Hradec Kralove Czech Republic

Zobrazit více v PubMed

Cancer. 2001 Jan 1;91(1):80-9 PubMed

Gynecol Oncol. 2008 Mar;108(3):555-60 PubMed

Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1345-51 PubMed

Gynecol Oncol. 2004 Sep;94(3):636-42 PubMed

Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):973-82 PubMed

BMC Cancer. 2008 Aug 12;8:232 PubMed

Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1165-72 PubMed

Anticancer Res. 2007 May-Jun;27(3B):1609-15 PubMed

Int J Gynecol Cancer. 2005 Mar-Apr;15(2):278-84 PubMed

Int J Gynecol Pathol. 1996 Jan;15(1):23-7 PubMed

Br J Cancer. 2000 Sep;83(5):620-5 PubMed

Gynecol Oncol. 2009 Mar;112(3):583-9 PubMed

Cancer. 2000 Jun 15;88(12):2766-73 PubMed

Gynecol Oncol. 2003 Nov;91(2):346-53 PubMed

J Korean Med Sci. 2004 Oct;19(5):693-7 PubMed

Gynecol Oncol. 2003 Jan;88(1):22-8 PubMed

Ceska Gynekol. 2006 Jul;71(4):308-11 PubMed

Lancet. 2001 Sep 8;358(9284):781-6 PubMed

Acta Medica (Hradec Kralove). 2008;51(2):95-9 PubMed

Ceska Gynekol. 2007 Apr;72(2):126-30 PubMed

Gynecol Oncol. 1996 Nov;63(2):216-8 PubMed

Radiother Oncol. 1995 Oct;37(1):1-9 PubMed

Gynecol Oncol. 2000 Nov;79(2):300-4 PubMed

Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):922-8 PubMed

Clin Cancer Res. 2009 Dec 1;15(23):7389-97 PubMed

J Pathol. 1999 Sep;189(1):1-3 PubMed

Cancer Detect Prev. 1998;22(2):120-8 PubMed

Gynecol Oncol. 2005 Nov;99(2):415-21 PubMed

J Cancer Res Clin Oncol. 1998;124(8):456-61 PubMed

Neoplasma. 2011;58(6):469-75 PubMed

Int J Gynecol Cancer. 2003 Nov-Dec;13(6):849-55 PubMed

Hypersensitivity to chemoradiation in FANCA carrier with cervical carcinoma-A case report and review of the literature